57328-75-3

Basic information

• Product Name: L-Tyrosine, glycyl-, methyl ester, monohydrochloride
• CAS NO: 57328-75-3
• Molecular Formula: C12H16N2O4.ClH
• Molecular Weight: 288.731
• Mol File: 57328-75-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: L-Tyrosine, glycyl-, methyl ester, monohydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: L-Tyrosine, glycyl-, methyl ester, monohydrochloride(57328-75-3)
• EPA Substance Registry System: L-Tyrosine, glycyl-, methyl ester, monohydrochloride(57328-75-3)

Safety Data

• Hazardous Substances Data: 57328-75-3(Hazardous Substances Data)

Upstream product

• 20803-44-5 N-Phthaloyl-glycyl-tyrosin-methylester 
• 1080-06-4 L-Tyr-OMe 
• 60-18-4 L-tyrosine 
• 188783-07-5 N-[N-(2-benzoyl-2-ethoxycarbonylvinyl-1)glycyl]-L-tyrosine methyl ester 
• 6913-23-1 2-thioxo-thiazolidin-5-one 

Relevant articles and documents

Novel thiazolidinedione-5-acetic-acid-peptide hybrid derivatives as potent antidiabetic and cardioprotective agents

Thiazolidinediones (TZDs) are one of the important clinically established antidiabetic agents. Amino-acid and peptides have an advantage of better target selectivity and specificity. As hybrids, they also improved absorption and showed better bioavailability, which in turn makes them safer. Hence, here an effort has been made to synthesize hybrids of thiazolidinedione with amino-acids and peptides and evaluate their antidiabetic and cardioprotective effect in streptozotocin-nicotinamide (STZ-NA) induced Type 2 diabetes mellitus (T2DM) rat models. A series of 14 thiazolidinedione-5-acetic acid hybrids with of different amino-acids and peptide combinations were synthesized, characterized and further screened for antidiabetic and cardioprotective activity. Among all, six compounds T1 (SSDMA1), T4 (SSDMA4), T5 (SSDMA5), T7 (SDMA13), T9 (SSDMA15) and T13 (SSDMA49) showed better antioxidant activity and comparable % glucose uptake by yeast cells. Hence, the in vivo antidiabetic screening was done for these six compounds. Among all six T1, T7, T13 showed significant blood glucose level decrease compared to standard pioglitazone HCl. Also T1, T7 and T13 showed better antioxidant activity with lower IC50 value than standard ascorbic acid, and hence in vivo cardioprotective studies were done for these. The ECG studies showed that T1 (SSDMA1) and T7 (SSDMA13) were better effective than SDMA49 (T13) in restoring the normal functioning of the heart, thus may help in preventing the development of diabetic cardiomyopathy (DCM) and controlling T2DM.